Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
PHASE2CompletedINTERVENTIONAL
Enrollment
47
Participants
Timeline
Start Date
July 30, 2007
Primary Completion Date
May 9, 2011
Study Completion Date
December 23, 2012
Conditions
Leukemia, Acute MyeloidMyelodysplastic Syndrome
Interventions
DRUG
temozolomide
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00687323 - Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052) | Biotech Hunter | Biotech Hunter